UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3025% above fair value
$591.17−2.14 (-0.36%)
Close on Nov 13, 2026Market cap $25.36BP/E 22.3Yield –
United Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
United Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 86.3%. For fiscal 2025 it was 87.9%, against 89.2% the year before. The highest annual figure on record is 95.5% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.9% | −1.3 |
| FY2024 | Dec 31, 2024 | 89.2% | +0.3 |
| FY2023 | Dec 31, 2023 | 88.9% | −3.2 |
| FY2022 | Dec 31, 2022 | 92.2% | −0.6 |
| FY2021 | Dec 31, 2021 | 92.7% | +0.0 |
| FY2020 | Dec 31, 2020 | 92.7% | +0.8 |
| FY2019 | Dec 31, 2019 | 91.9% | +4.1 |
| FY2018 | Dec 31, 2018 | 87.8% | −6.1 |
| FY2017 | Dec 31, 2017 | 93.9% | −1.6 |
| FY2016 | Dec 31, 2016 | 95.5% | +0.2 |
| FY2015 | Dec 31, 2015 | 95.3% | +5.8 |
| FY2014 | Dec 31, 2014 | 89.5% | +2.2 |
| FY2013 | Dec 31, 2013 | 87.4% | +1.5 |
| FY2012 | Dec 31, 2012 | 85.9% | −1.9 |
| FY2011 | Dec 31, 2011 | 87.8% | −0.6 |
| FY2010 | Dec 31, 2010 | 88.4% | +0.1 |
| FY2009 | Dec 31, 2009 | 88.3% | −2.2 |
| FY2008 | Dec 31, 2008 | 90.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 88.1% | +0.7 |
| Q2 FY2026 | Jun 30, 2026 | 87.3% | −1.7 |
| Q1 FY2026 | Mar 31, 2026 | 82.9% | −5.4 |
| Q4 FY2025 | Dec 31, 2025 | 86.9% | −2.8 |
| Q3 FY2025 | Sep 30, 2025 | 87.4% | −1.5 |
| Q2 FY2025 | Jun 30, 2025 | 89.0% | −0.1 |
| Q1 FY2025 | Mar 31, 2025 | 88.4% | −0.9 |
| Q4 FY2024 | Dec 31, 2024 | 89.7% | +1.2 |
| Q3 FY2024 | Sep 30, 2024 | 88.9% | +0.4 |
| Q2 FY2024 | Jun 30, 2024 | 89.1% | −0.1 |
| Q1 FY2024 | Mar 31, 2024 | 89.2% | −0.4 |
| Q4 FY2023 | Dec 31, 2023 | 88.4% | +0.4 |
| Q3 FY2023 | Sep 30, 2023 | 88.5% | −4.3 |
| Q2 FY2023 | Jun 30, 2023 | 89.3% | −4.4 |
| Q1 FY2023 | Mar 31, 2023 | 89.7% | −4.7 |
| Q4 FY2022 | Dec 31, 2022 | 88.0% | −3.6 |
| Q3 FY2022 | Sep 30, 2022 | 92.8% | −1.0 |
| Q2 FY2022 | Jun 30, 2022 | 93.6% | +2.0 |
| Q1 FY2022 | Mar 31, 2022 | 94.4% | +0.5 |
| Q4 FY2021 | Dec 31, 2021 | 91.7% | +0.7 |
| Q3 FY2021 | Sep 30, 2021 | 93.8% | +0.1 |
| Q2 FY2021 | Jun 30, 2021 | 91.7% | −1.2 |
| Q1 FY2021 | Mar 31, 2021 | 93.9% | +0.5 |
| Q4 FY2020 | Dec 31, 2020 | 91.0% | +0.2 |
| Q3 FY2020 | Sep 30, 2020 | 93.7% | +1.9 |
| Q2 FY2020 | Jun 30, 2020 | 92.8% | −0.0 |
| Q1 FY2020 | Mar 31, 2020 | 93.4% | +1.5 |
| Q4 FY2019 | Dec 31, 2019 | 90.7% | −0.9 |
| Q3 FY2019 | Sep 30, 2019 | 91.8% | +4.4 |
| Q2 FY2019 | Jun 30, 2019 | 92.9% | +6.7 |
| Q1 FY2019 | Mar 31, 2019 | 92.0% | +5.6 |
| Q4 FY2018 | Dec 31, 2018 | 91.6% | +3.0 |
| Q3 FY2018 | Sep 30, 2018 | 87.4% | −8.2 |
| Q2 FY2018 | Jun 30, 2018 | 86.1% | −9.6 |
| Q1 FY2018 | Mar 31, 2018 | 86.3% | −9.8 |
| Q4 FY2017 | Dec 31, 2017 | 88.6% | −4.5 |
| Q3 FY2017 | Sep 30, 2017 | 95.6% | – |
| Q2 FY2017 | Jun 30, 2017 | 95.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 96.1% | – |
| Q4 FY2016 | Dec 31, 2016 | 93.1% | – |
See a number that looks wrong?